Votrient: first targeted oral therapy for advanced soft tissue sarcoma

Votrient (pazopanib) has been approved as a treatment option for advanced soft tissue sarcoma (STS).

by
Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.
Votrient is also licensed for advanced renal cell carcinoma, as first line treatment or following cytokine therapy.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package